Additionally, evaluating differential effects of DNA-damaging agents on the p53 response may inform combination treatments that optimize the induction of p53-mediated apoptosis in cancer cells and/or enhance the p53-mediated anti-tumor immune response. Here, TP53 is linked to cancer.